Abstracts tagged "Therapy, alternative"

Abstract Number: 0268 • ACR Convergence 2025
Multicenter study and literature review of JAK inhibitor treatment in refractory uveitis due to different immune-mediated inflammatory pathologies
Nuria Barroso Garcia¹, Lara Sánchez Bilbao², José Luis Martín-Varillas³, Vanesa Calvo-Río², Mar Esteban Ortega⁴, Santiago muñoz Fernández⁵, José Luis Álvarez-Vega⁶, Emma Beltran⁷, Vega Jovaní⁸, Olga Maiz Alonso⁹, raúl Veroz González¹⁰, Angel Garcia-Aparicio¹¹, marta Garijo Bufort¹² and Ricardo Blanco², ¹Rheumatology, Hospital Regional Universitario, Universidad de Málaga UMA, Málaga, Spain, Malaga, Spain, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ⁴Rheumatology and Ophthalmology. Hospital Infanta Sofía. Madrid. Spain, Madrid, Spain, ⁵Rheumatology and Ophthalmology. Hospital Infanta Sofía, Madrid. Spain, Madrid, ⁶Rheumatology. Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Badajoz, Spain, ⁷Rheumatology. Hospital del Mar. Barcelona, Spain., Barcelona, Spain, ⁸Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ⁹Rheumatology. Hospital de Donostia. San Sebastián, Spain., San Sebastián, Spain, ¹⁰Rheumatology. Hospital de Mérida. Mérida, Spain., Mérida, Spain, ¹¹Hospital Universitario de Toledo, Toledo, Spain, ¹²Rheumatology Department, Hospital de Sagunto, Spain, Valencia, Spain
Background/Purpose: Non-infectious uveitis may be related to several immune-mediated diseases (IMIDs). Those that are refractory to conventional therapy or biologics may lead to severe ocular…
Abstract Number: 1599 • ACR Convergence 2025
Cyclophosphamide versus Rituximab in the treatment of Anca-associated Vasculitis: Adverse events and Relapses
Fabricio Benavides Villanueva¹, Diana Prieto-Peña², Vanesa Calvo-Río³, Monica Renuncio-García⁴, Adrian Martin-Gutierrez⁵, Amparo Sanchez-Lopez⁶, Claudia Poo-fernandez⁷, maria Rodríguez-Vidriales⁸ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁶Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁷Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). EGPA presents a different pathogenic,…
Abstract Number: 0370 • ACR Convergence 2025
Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device
Jeffrey Curtis¹, Joshua Baker², Shilpa Venkatachalam³, Sherry Danese⁴, Julie Ulloa⁵ and Ankit Shah⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³Global Healthy Living Foundation, New York, NY, ⁴OutcomesInsights, Calabasas, CA, ⁵OutcomesInsights, Calabasas, ⁶SetPoint Medical, Valencia, CA
Background/Purpose: Despite broadening treatment options for RA, several challenges and unmet needs remain. The 2021 ACR guideline for the treatment of RA marked a significant…
Abstract Number: 1600 • ACR Convergence 2025
Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study
Fabricio Benavides Villanueva¹, Andrea Tristan-Alonso², Carlos Martinez-Rivera³, Alicia Padilla-Galo⁴, Marina Blanco-Aparicio⁵ and Ricardo Blanco⁶, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Pneumology, Hospital Universitario Puerta del Hierro, Madrid, Spain, Majadahonda, Madrid, Spain, ³Division of Pneumology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁴Division of Pneumology, Hospital Universitario Virgen de la Victoria, Málaga, Spain, Malaga, Andalucia, Spain, ⁵Division of Pneumology, Hospital Universitario A Coruña, A Coruña, Spain, A coruña, Galicia, Spain, ⁶Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Benralizumab is approved for eosinophil-driven conditions, like eosinophilic asthma. Recently, the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) authorized its…
Abstract Number: 0429 • ACR Convergence 2025
Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Xuemei Tang¹, Xiwen Luo², Xiya Luo¹, Mengwei Ding³, Xi Yang², Dawei Liu², Li Xu², Zhiyong Zhang², Yunfei An² and Xiaodong Zhao¹, ¹Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), ²Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), ³Big Data Center for Children’s Medical Care, Children’s Hospital of Chongqing Medical University, Chongqing, China., Chongqing, China (People's Republic)
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease. Some patients experiencing active disease due to inadequate responses to conventional treatments. Studies have demonstrated…
Abstract Number: 1675 • ACR Convergence 2025
Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)
Guillermo Valenzuela¹, Jane Box², Angela Crowley³, Joshua June⁴, Pendleton Wickersham⁵, Jeff Peterson⁶, Michael Thakor⁷, Susan Kim⁸, Tina Shah⁹, David Chernoff¹⁰ and John Tesser¹¹, ¹Integral Rheumatology & Immunology Specialists, Plantation, FL, ²DJL Clinical Research, PLLC, Charlotte, NC, ³Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Western Washington Arthritis Clinic, Seattle, WA, ⁷arthritis and rheumatology, Fort Collins, CO, ⁸Lehigh Valley Hospital Network, Allentown, PA, ⁹Kansas City Physician Partners, Kansas City, MO, ¹⁰SetPoint Medical, Sausalito, CA, ¹¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ
Background/Purpose: A substantial number of patients with rheumatoid arthritis (RA) experience treatment failure, incomplete response, or intolerance to TNFis (TNFi-IR). Neuroimmune modulation using an implantable…
Abstract Number: 0877 • ACR Convergence 2025
Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
Rodrigo García Salinas¹, Gisel Reyes-Jara², Felicia Almada³, Juan Arguello² and Sebastian Magri⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano de La Plata, La Plara, Argentina, ⁴Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: The transition from psoriasis (Pso) to psoriatic arthritis (PsA) presents an opportunity for early intervention and preventive strategies in high-risk patients with arthralgia. Objectives:…
Abstract Number: 1875 • ACR Convergence 2025
Fcγ-receptor activation by circulating immune complexes in autoimmunity and CD19.CAR-T cell therapy
Merle Freitag¹, Maren Claus², Philippe Kolb³, Valeria Falcone⁴, Ivana Andreeva¹, Norbert Blank⁵, Hanns-Martin Lorenz⁶, Georg Schett⁷ and Wolfgang Merkt⁸, ¹Uniklinik Heidelberg, Heidelberg, Germany, ²IfADo, Leibniz Institute Dortmund, Dortmund, Germany, ³INSTITUTE OF VIROLOGY Medical Center, Freiburg, Freiburg, Germany, ⁴University Medical Center, Freiburg, Freiburg, Germany, ⁵University Hospital Heidelberg, Heidelberg, Germany, ⁶Universitétsklinikum Heidelberg, Heidelberg, Germany, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: The role of autoantibodies in systemic autoimmunity, such as connective tissue diseases (CTD), has been recently highlighted by the successful treatment with CD19-targeting CAR-T…
Abstract Number: 0554 • ACR Convergence 2025
Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India
Sanjeev Kapoor¹, Babita Bondage¹, Niti Kedia¹, Mariya Patel¹ and Akanksha Kapoor², ¹Indian Spinal Injuries Centre (ISIC), New Delhi, India, ²Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital, Pune, India
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory condition that falls under the category of spondyloarthritis (SpA) and significantly affects quality of life, causing symptoms like…
Abstract Number: 1876 • ACR Convergence 2025
Targeting the NK cell checkpoint NKG2A promotes lung fibrosis resolution by enhancing immune clearance of senescent myofibroblasts
Wolfgang Merkt¹, Lea Rodon², Franca Sophie Deicher³, Maren Claus⁴, Rachel Lister⁵, Hongwei Han⁵, Yan Zhou⁵, Zhengwang Sun⁵, Arik Horne⁶, Ayla Nadja Stuetz⁷, Michael Kreuter⁸, nicolas kahn⁹, Marc Schneider⁹, Simon Haas¹⁰, Norbert Blank¹¹, Hanns-Martin Lorenz¹², Carsten Watzl⁴, Daniel Hübschmann¹³ and David Lagares⁵, ¹University Hospital Düsseldorf, Düsseldorf, Germany, ²University Hospital Heidelberg, Heidelberg, Hungary, ³Uniklinik Düsseldorf, Düsseldorf, Germany, ⁴IfADo, Leibniz Institute Dortmund, Dortmund, Germany, ⁵Massachusetts General Hospital and Harvard Medical School, Boston, ⁶Charite, Berlin, Berlin, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ⁸Universitätsmedizin Mainz, Mainz, ⁹Thoraxklinik, Heidelberg University, Heidelberg, Germany, ¹⁰Charite, Berlin, Berlin, Germany, ¹¹University Hospital Heidelberg, Heidelberg, Germany, ¹²Universitétsklinikum Heidelberg, Heidelberg, Germany, ¹³Heidelberg University, Berlin, Germany
Background/Purpose: A key event driving pulmonary fibrosis in interstitial lung disease (ILD) is the accumulation of pathologic senescent myofibroblasts, thought to be promoted by insufficient…
Abstract Number: 0565 • ACR Convergence 2025
Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
Andre Lucas Ribeiro¹, Virginia Carrizo Abarza², Jensen Yeung³, Khalad Maliyar³, Siddhartha Sood³, Ahmet Bagit³, Muskaan Sachdeva³, Sahil Koppikar⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Lihi Eder⁶, ¹Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³Women's College Hospital & University of Toronto, Toronto, ON, Canada, ⁴Women's College Hospital & University of Toronto, Markham, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Despite advances in psoriatic arthritis (PsA) treatment, remission remains elusive for many patients. This has prompted growing interest in combining biologic and targeted synthetic…
Abstract Number: 2042 • ACR Convergence 2025
Safety and Effectiveness of the Use of Combined Therapy with bDMARDS and tsDMARDs in Immune-mediated Inflammatory Diseases
Natalia Lopez Juanes¹, Carlota Ureta¹, Marta Novella-Navarro¹, Irene Monjo Henry¹, Diana Peiteado¹, Alejandro Villalba¹, Laura Nuño², Victoria Navarro-Compan³, María Sanz¹, Mª ángeles Gonzalez¹, Cristina Suarez⁴, Agustin Remesal¹, Rosa Alcobendas⁵, Clara udaondo¹, Elena Sendagorta⁵, Alejandro Balsa¹, Eugenio de Miguel¹ and Chamaida Plasencia-Rodríguez¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁵La Paz University Hospital, Madrid, Spain
Background/Purpose: The combination of biological (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has emerged as a promising approach to improve clinical outcomes in immune-mediated inflammatory diseases…
Abstract Number: 0582 • ACR Convergence 2025
Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
Prabhu Vasantha Kumar¹, John Mathew², Ashish Jacob Mathew³ and Ruchika Goel², ¹Christian Medical College, Vellore, Tamil Nadu, India, Vellore, Tamil Nadu, India, ²Christian Medical College, Vellore, Tamil Nadu, India, ³Christian Medical College, Vellore, India
Background/Purpose: Despite the good efficacy of bDMARDs in nearly 60% of patients with axial spondyloarthritis (AxSpA), high costs limit their use in resource-limited settings. Few…
Abstract Number: 2278 • ACR Convergence 2025
Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
John Tesser¹, Angela Crowley², Jane Box³, Joshua June⁴, Pendleton Wickersham⁵, Guillermo Valenzuela⁶, Norman Gaylis⁷, Gordon Lam⁸, Leroy Pacheco⁹, David Ridley¹⁰, Gineth Pinto-Patarroyo¹¹, Stuart Novack¹², Melvin Churchill¹³, Minna Kohler¹⁴, Eric Lee¹⁵, Jose A Pando¹⁶, Glenn R. Parris¹⁷, Jeff Peterson¹⁸, Tina Shah¹⁹, Atul Singhal²⁰, Victoria Vuong²¹, Jeffrey Curtis²² and David Chernoff²³, ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ³DJL Clinical Research, PLLC, Charlotte, NC, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁸Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ⁹Albuquerque Ctr for Rheumatology, Albuquerque, NM, ¹⁰Saint Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Herndon, VA, ¹²Nuvance Health network, NORWALK, CT, ¹³Arthritis Center of Nebraska, Lincoln, NE, ¹⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁵Inland Rheumatology and Osteoporosis Medical Group, Upland, CA, ¹⁶Delaware Arthritis, Lewes, DE, ¹⁷PARRIS & ASSOCIATES, Lilburn, GA, ¹⁸Western Washington Arthritis Clinic, Seattle, WA, ¹⁹Kansas City Physician Partners, Kansas City, MO, ²⁰SouthWest Arthritis Research Group, Mesquite, TX, ²¹Long Island Regional Arthritis & Osteoporosis Care, Hicksville, NY, ²²University of Alabama at Birmingham, Birmingham, AL, ²³SetPoint Medical, Sausalito, CA
Background/Purpose: Neuroimmune modulation by electrical stimulation of the left cervical vagus nerve represents a novel treatment option for rheumatoid arthritis (RA). We present 12-month efficacy…
Abstract Number: 0584 • ACR Convergence 2025
Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
Rodrigo García Salinas¹, Nataly Mejia², Santiago Ruta³ and Sebastian Magri⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital San Martin de La Plata, La Plata, Argentina, ⁴Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: The concept of difficult-to-Manage axial spondyloarthritis (axSpA D2M), recently introduced by ASAS, describes patients who fail ≥2 lines of b-tsDMARDs treatment and remain active…

1
2
3
…
7
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].